Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.
H'ability
Seed Round in 2025
H'ability specializes in providing immersive virtual reality (VR) therapeutic exercises that complement traditional rehabilitation methods. The company offers a wireless VR headset with customizable exercises targeting motor skills, balance, and cognitive functions. Their platform features real-time session personalization, detailed progress tracking with data analytics, and compatibility with additional rehabilitation tools. This enables healthcare professionals to deliver personalized, engaging, and efficient therapy sessions in clinical settings or at patients' homes, catering to various medical conditions.
Fizimed
Venture Round in 2025
Fizimed SAS is a French company based in Strasbourg that specializes in developing medical devices aimed at addressing urinary incontinence in women. The company's flagship product, EMY, is a perineal probe designed to facilitate pelvic floor muscle reeducation. EMY connects to a mobile application, allowing users to engage in customized, interactive exercises that strengthen their pelvic floor while tracking their progress in real time. The device incorporates gamified elements to motivate users, offering various activities that turn exercises into enjoyable challenges. Founded in 2017, Fizimed is committed to balancing the safety and quality of medical devices with user-friendly technology, while actively working to destigmatize urinary incontinence—a common issue affecting one in ten women. Through social media initiatives, Fizimed fosters a community that encourages open discussions around this topic, aiming to empower women to take control of their health and well-being.
Superbranche
Venture Round in 2025
Superbranche is a biotechnology company specializing in the early detection and treatment of metastases. It develops therapeutic and diagnostic applications using nanotechnological provisions, aiming to improve accessibility and enable early tumor detection.
Vetbiolix
Venture Round in 2024
Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.
Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.
Vetbiolix
Seed Round in 2024
Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.
Hepta Medical
Series A in 2024
Hepta Medical develops a microwave ablation platform designed for minimally invasive, nonsurgical treatment of early lung cancer. Its proprietary technology features an ablation catheter with integrated temperature sensing, enabling real-time monitoring and control of tissue ablation size.
Archeon Medical
Venture Round in 2024
Archeon Medical specializes in the development of innovative solutions aimed at enhancing the monitoring, diagnosis, and treatment of critically ill patients during prehospital care. The company utilizes artificial intelligence to create disruptive technologies that focus on improving ventilation quality in emergency medical services. Archeon Medical's products are practical, easy to use, and intuitive, providing emergency caregivers with real-time feedback on the quality of ventilation administered to patients. Through its commitment to advancing prehospital care, Archeon Medical seeks to optimize patient outcomes in critical situations.
UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.
May Health
Series B in 2024
May Health is a healthcare company focused on addressing infertility related to Polycystic Ovary Syndrome (PCOS). The company has developed an innovative, minimally invasive procedure aimed at restoring ovulation in women with PCOS. This one-time treatment is performed transvaginally under ultrasound guidance, allowing for its execution in a clinical setting without the need for general anesthesia. May Health's approach seeks to provide patients with a more natural pregnancy experience by assisting the body to ovulate as it would naturally, thereby offering a less medicalized alternative to traditional fertility treatments.
Pixacare
Venture Round in 2024
Pixacare is a medical imaging platform that converts smartphones into secure documentation tools for wound care. The app enables healthcare professionals to capture, manage, and monitor wound images and associated data, integrating with patient administration systems and electronic health records to streamline workflows. It supports home-care staff, surgeons, and dermatologists in monitoring chronic and post-surgical wounds, predicting complications, and saving time on visual assessments. The solution is CE-marked as a Class I digital medical device and is hosted on certified health data infrastructure to ensure data security and interoperability with healthcare IT systems.
Tribun Health
Grant in 2024
Tribun Health specializes in digital health solutions for cancer detection. It develops innovative systems that enable diagnostic laboratories and pharmaceutical/biotech companies to manage, analyze, and share cellular images efficiently.
Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.
Pixee Medical
Series B in 2024
Founded in 2017, Pixee Medical specializes in manufacturing medical equipment that aids in precise implant positioning. Utilizing computer vision and AI technologies, their camera-based systems enable surgeons to navigate prostheses with millimeter precision using smart glasses, enhancing orthopedic surgery affordability.
Vulkam
Debt Financing in 2023
Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.
Vulkam
Venture Round in 2023
Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.
Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.
Callyope
Seed Round in 2023
Callyope is a technology company focused on enhancing brain health monitoring through human-centered solutions. By developing a speech-based platform that utilizes natural language processing and signal processing techniques, Callyope enables caregivers to monitor patients' brain functionality more effectively. The platform allows for a detailed examination of patients' verbal productions, providing valuable insights that help identify relapses and inform treatment decisions. Ultimately, Callyope aims to improve the quality of life for patients while also contributing to a reduction in re-hospitalization rates.
Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.
Injectpower specializes in developing energy storage technologies and micro-batteries tailored for medical implants. Their core product is a small, solid-state battery that powers implantable devices, enabling them to function as sensors or actuators for extended periods without the need for recharging. With over 16 years of research and 40 patents, Injectpower's batteries are manufactured using a proven semiconductor supply chain, ensuring high reliability. The company's innovative solutions include batteries for devices that monitor intraocular pressure in glaucoma patients and intracranial pressure and fluid flow, allowing physicians to remotely monitor and diagnose conditions more effectively.
Diamidex
Debt Financing in 2023
Diamidex SAS, established in 2014 and based in Marseille, France, specializes in the development and production of rapid detection tests for legionella, a type of bacteria that can cause severe lung infections. The company offers turnkey test solutions, designed for both laboratory and field use, which provide semi-quantitative counts of microorganisms in water samples and industrial goods. Diamidex's products aim to enhance the accuracy and speed of microbial contamination detection, facilitating more efficient screening and data collection in research and testing environments.
Resolve Stroke
Seed Round in 2023
Resolve Stroke, headquartered in Paris, is a HealthTech company dedicated to revolutionizing medical imaging. It specializes in enhancing ultrasound technology to extract more detailed information, enabling advanced diagnostics, particularly in neurology. The company's innovative software engines improve ultrasound contrast, resolution, and penetration depth, allowing for the visualization of micro-vessels through the human skull in 3D. With a global focus, Resolve Stroke aims to accelerate treatments for over 1 billion people affected by brain diseases. To date, it has secured €3 million in pre-seed funding to pioneer software-based ultrasound innovation.
Tribun Health
Series B in 2023
Tribun Health specializes in digital health solutions for cancer detection. It develops innovative systems that enable diagnostic laboratories and pharmaceutical/biotech companies to manage, analyze, and share cellular images efficiently.
GenSensor
Seed Round in 2023
GenSensor is a biotechnology company that specializes in developing and implementing a genomic-based, in-line bioproduction monitoring system. This system combines a robotic device with advanced analytics software to monitor, characterize, and optimize the production of advanced therapy medicinal products (ATMPs) and vaccines. By providing real-time insights into the bioproduction process, GenSensor helps healthcare companies maximize the use of innovative drugs, improve production efficiency, and ultimately reduce manufacturing costs, thereby benefiting patients.
X-Pressure
Seed Round in 2023
X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.
SMAIO is a manufacturer of medical devices for spinal pathologies. They provide control over surgical procedures to the spine physician through a range of solutions.
CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.
Hemerion Therapeutics
Seed Round in 2023
Hemerion Therapeutics specializes in developing innovative cancer treatments, with a primary focus on advanced methods for treating glioblastoma, the most common and aggressive form of primary brain tumour. The company's proprietary platform combines photosensitizing molecules with advanced laser light technologies to enable precise targeting of resistant tumours.
Dianosic
Seed Round in 2023
Founded in 2017, Dianosic specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. The company's flagship product is the Active Resorbable Intranasal Scaffold (ARIS), a long-acting, patient-friendly device designed to treat chronic rhinitis and sinusitis, offering an alternative to daily medication.
Orthopus
Seed Round in 2023
Orthopus manufactures and distributes medical devices. They develop a range of robotic devices for arm mobility. Their supporter compensates for the weight of the arm to facilitate vertical movements. Their robotic device is used in an electric wheelchair and on a table.
Ganymed Robotics
Debt Financing in 2023
Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.
Clarity
Pre Seed Round in 2022
Clarity is a clinical-stage company pioneering a new category of non-pharmacological treatments for neurodegenerative diseases. We develop a neuromodulation device combining immersive technology, AI and biosensors to deliver gamma sensory stimulation.
Gamma waves’ sensory stimulation has been shown to significantly slow down Alzheimer's progression, reducing neurodegeneration and cognitive decline. Clarity takes a platform approach by enabling the customization of sensory stimulation protocols based on patient data, improving experience, efficacy and scalability across a wide range of indications. The company was founded by neuroscientists from UC Berkeley, and Oxford along with execs from OURA and Philips, and is supported by leading institutions such as UCSF's Neuroscape.
Remedee Labs
Series A in 2022
Remedee Labs SAS is a French company founded in 2016, dedicated to developing innovative solutions for chronic pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a personal endorphin stimulator that facilitates on-demand stimulation of the body’s natural endorphins to alleviate pain. Drawing on a decade of pre-clinical and clinical research, Remedee Labs aims to improve the quality of life for the 1.5 billion people worldwide suffering from chronic pain, particularly focusing on conditions such as fibromyalgia. By collaborating with medical practitioners, the company offers a patient-centered digital service platform that enhances the accessibility and effectiveness of endorphin-stimulation therapy for personal healthcare. As it continues to evolve, Remedee Labs plans to expand its platform to address additional chronic pain conditions, positioning itself as a leader in neuromodulation technology for pain management.
Meccellis Biotech
Debt Financing in 2022
Founded in 2013, Meccellis Biotech specializes in the development of biological implants for tissue repair. Utilizing tissue and cellular engineering, they offer solutions tailored to various surgical specialties.
Livmed's
Seed Round in 2022
Livmed's is a software platform based in Nice, France, that specializes in home medicine delivery services. Founded in 2020, the company enables individuals to receive both prescription and non-prescription medications directly at their homes. The platform operates around the clock, ensuring timely access to essential healthcare products. Livmed's facilitates medicine delivery from local drugstores, allowing customers to obtain their medications conveniently, whether they have a prescription or not. Through its innovative approach, Livmed's enhances accessibility to healthcare while streamlining the medication procurement process for users.
Guerbet Group
Post in 2022
Guerbet is a healthcare company focused on medical imaging, with a history spanning 90 years. As a pioneer in contrast media, it is the only pharmaceutical group dedicated exclusively to this field. Guerbet operates in nearly 80 countries through a network of subsidiaries and distributors, providing a wide array of products for various imaging modalities, including CT scans, magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company’s portfolio includes well-known brands such as Xenetix, Optiray, Dotarem, and Telebrix, among others. Additionally, Guerbet offers injectors and related medical devices aimed at enhancing patient diagnosis, prognosis, and overall quality of life.
Incepto Medical
Venture Round in 2022
Founded in 2018, Incepto Medical develops AI-driven medical imaging applications. Its products include Qure.ai qER for head CTs, Qure.ai qXR for thorax abnormalities, Aidence Veye Chest for pulmonary nodule tracking, Icometric Icobrain for neurological disorder monitoring, and ScreenPoint Transpara for breast cancer detection. The company also operates Collective Minds Radiology, an online platform for case support and learning.
Carroucell
Series A in 2022
Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.
Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.
Qairn is a company that specializes in digitizing regulatory processes through its software-as-a-service (SaaS) platform. This platform is designed to streamline and secure mandatory procedures for various healthcare sectors, including laboratories, medical device manufacturers, and biotechnology firms. Qairn offers services such as the review and validation of promotional materials, submission to the ANSM, and the validation of regulated content. By simplifying these processes, Qairn helps healthcare manufacturers manage their regulatory requirements efficiently, thereby reducing risks associated with compliance and enhancing workflow management.
Nurea develops AI-powered medical imaging software that transforms standard 2D scans into 3D reconstructions of arterial systems, enabling early detection of cardiovascular and neurovascular conditions such as aneurysms. The solution automates quantitative image analysis, providing accurate, operator-independent assessments that integrate seamlessly into hospital workflows. By allowing clinicians to monitor structural changes over time, the platform supports precise and reliable diagnoses for vascular surgeons and other healthcare professionals.
Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.
Healshape
Venture Round in 2022
Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women through innovative regenerative medicine techniques. The company specializes in creating bioprostheses using 3D bioprinting technology, offering an alternative to traditional breast reconstruction methods. By focusing on natural products, Healshape aims to provide women with long-lasting, aesthetically pleasing results, helping them regain their self-confidence following surgery.
Intradys
Seed Round in 2022
Intradys develops medical software technologies for interventional neuroradiology. It creates algorithms that fuse machine learning with mixed reality to help clinicians determine optimal strategies based on patient factors such as age and prior history, and the suitability of devices to the pathology. The software relies on imaging acquired before and during procedures to enable neuroradiologists to make informed decisions in the operating room.
Diabeloop
Debt Financing in 2022
Diabeloop is a medical device company based in Grenoble, France, specializing in innovative solutions for diabetes management. Founded in 2015, the company focuses on developing a closed-loop system that automates insulin delivery for individuals with type 1 diabetes. Its AI-based blood sugar monitoring device integrates a sensor that continuously measures glucose levels, a pump that administers insulin, and a smartphone application that connects these components through an embedded algorithm. This technology aims to enhance the treatment experience by reducing the mental burden on patients, allowing them to manage their condition more effortlessly and live their lives with greater freedom.
Hemerion Therapeutics
Debt Financing in 2022
Hemerion Therapeutics specializes in developing innovative cancer treatments, with a primary focus on advanced methods for treating glioblastoma, the most common and aggressive form of primary brain tumour. The company's proprietary platform combines photosensitizing molecules with advanced laser light technologies to enable precise targeting of resistant tumours.
Guard Medical
Series B in 2022
Guard Medical specializes in developing innovative medical devices. Its flagship product is NPsealâ„¢, designed to facilitate easy-to-use and cost-effective negative pressure wound therapy for closed surgical incisions.
LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.
Cairdac is a medical technology company developing a self-sustaining, leadless pacing system. Its proprietary piezoelectric energy harvester and miniaturized ASIC enable the device to harvest kinetic energy from the heart, providing a lifespan of over 15 years. The ALPSTM pacemaker is autonomously implanted via endoscopy, offering a cost-effective solution for maintaining cardiac rhythm.
Archeon Medical
Series A in 2022
Archeon Medical specializes in the development of innovative solutions aimed at enhancing the monitoring, diagnosis, and treatment of critically ill patients during prehospital care. The company utilizes artificial intelligence to create disruptive technologies that focus on improving ventilation quality in emergency medical services. Archeon Medical's products are practical, easy to use, and intuitive, providing emergency caregivers with real-time feedback on the quality of ventilation administered to patients. Through its commitment to advancing prehospital care, Archeon Medical seeks to optimize patient outcomes in critical situations.
VistaCare is a French company specializing in innovative medical devices for treating acute and chronic wounds. It develops, manufactures, and distributes products designed to enhance patient quality of life and simplify caregiver routines by reducing treatment times and hospital stays.
Wandercraft
Series C in 2022
Wandercraft is a robotics company that develops self-balancing robotic exoskeletons to enable paralyzed users to stand and walk hands-free, without crutches. Its flagship exoskeleton, Atalante, is a commercial device designed for daily life and rehabilitation, CE-marked in 2019 and marketed to European rehab hospitals to support gait re-learning. The company combines algorithmics, AI, robotics, production, clinical, marketing and sales to deliver a full-stack solution and aims to bring a realistic, autonomous walking device beyond lab prototypes. The exoskeleton uses motors at each joint controlled by a computing unit running software that computes robotic algorithms every millisecond to replicate a human gait, enabling paraplegic individuals to regain autonomy during daily activities.
Spartha Medical
Seed Round in 2021
Spartha Medical is a medical technology company focused on developing innovative coatings designed to enhance the safety of medical devices and consumer products. The company utilizes eco-friendly and biocompatible coatings made from natural biopolymers, which possess antibacterial, antiviral, and anti-inflammatory properties. Their patented technology allows for precise control over the assembly of two distinct polyelectrolytes, enabling the creation of versatile and multifunctional surface coatings tailored to specific applications. By providing effective solutions that protect users from microbial and inflammatory risks, Spartha Medical aims to improve healthcare outcomes and promote safer use of medical devices across various healthcare settings.
Hypno VR SAS is a company that specializes in developing and operating virtual reality-based medical hypnosis solutions aimed at managing pain and stress. Founded in 2016 and headquartered in Strasbourg, France, Hypno VR creates applications designed to facilitate medical hypnosis during procedures, thereby reducing anxiety and discomfort for patients. The company's technology is particularly beneficial in various medical fields, including pediatric surgery, gastroenterology, gynecology, and dental surgery. In addition to its software solutions, Hypno VR also develops virtual reality hardware tailored for medical applications, catering to health professionals and institutions seeking innovative ways to enhance patient care.
Quantum Surgical
Venture Round in 2021
Quantum Surgical develops surgical robotics and intelligent tools to democratize minimally invasive liver cancer treatment. The company's robotics support percutaneous ablation therapies and related minimally invasive procedures, aiming to improve patient outcomes and safety in interventional oncology. By enabling precise robotic assistance, Quantum Surgical seeks to help healthcare providers perform safer, more effective liver cancer interventions, with potential for higher cure rates and shorter recovery times.
TreeFrog Therapeutics
Series B in 2021
TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.
UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.
Omini develops a portable, multiplex biosensor platform for blood testing that enables the simultaneous detection of multiple biomarkers. The device is designed for chronic disease monitoring and therapy management, providing personalized biomarker data to adjust treatments and help prevent acute crises, with applications for general practitioners. Incorporated in 2019 and based in Saint-Mandé, France, Omini aims to offer a low-cost, regular monitoring solution that supports routine assessment of complex conditions such as heart failure.
Grapheal
Seed Round in 2021
Grapheal is a Medtech startup specializing in embedded and wearable biosensors. Utilizing graphene transistors, their wireless sensors enable accurate field diagnostics and remote patient monitoring for various biomarkers and pathogens.
eCential Robotics
Venture Round in 2021
eCential Robotics specializes in minimally invasive surgical solutions aimed at enhancing routine clinical practices. The company develops advanced imaging technology that integrates fluoroscopy, surgical navigation, and robotics, specifically tailored for orthopedic and trauma surgeries. Its innovative system offers high-definition imaging and real-time navigation, allowing surgeons to conduct various procedures with increased safety and precision. By facilitating day surgery, eCential Robotics provides significant benefits to patients, hospitals, clinics, and overall healthcare systems, while also minimizing radiation exposure during complex interventions.
CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.
NovAliX
Venture Round in 2020
NovAliX specializes in supporting pharmaceutical industry outsourcing needs through advanced technologies. It offers integrated services for small molecule drug discovery using proprietary Surface Plasmon Resonance (SPR) technology, X-ray protein crystallography, supramolecular mass spectrometry, and chemistry. Additionally, NovAliX provides detailed characterization of biologics, API analysis, and polymorphism studies to aid pharmaceutical development and manufacturing.
In&Motion
Venture Round in 2020
In&Motion develops wearable smart protection systems designed to reduce injuries from falls. Its flagship ski airbag vest monitors skiers’ movements in real time to anticipate a fall and inflate the airbag before impact, protecting critical areas. The system relies on embedded sensors and algorithms to detect loss of balance and trigger inflation, enabling safety for athletes and enthusiasts alike. The technology has won awards and was worn by Ski Cross World Cup racers in 2015-16, with plans to be available in stores through a partner brand, POC.
TISSIUM
Debt Financing in 2020
TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.
Multiwave Technologies
Grant in 2020
Multiwave Technologies develops breakthrough magnetic resonance imaging and positron emission tomography devices, including metamaterial MRI antennas designed by its French unit. The company aims to improve MRI image quality and support clinical decision making, including portable MRI capabilities and sensor-based performance analysis. Founded in 2015 in Switzerland, it is headquartered in Geneva and conducts research and development in France, reflecting an international footprint. The business is recognized for its metamaterial MRI antenna design and positions itself as a deep science imaging innovator in neurology and other medical imaging applications.
Withings is a developer of digital health and wellness smart devices aimed at empowering individuals to make informed health decisions. The company offers a diverse array of products, including smart scales that help users achieve fitness and weight goals, stylish activity trackers and hybrid smartwatches, and an advanced sleep-tracking mat. Additionally, Withings produces medically accurate devices for monitoring blood pressure and temperature, enabling users to track their health progress effectively. These devices facilitate data sharing with healthcare professionals, enhancing the overall management of personal health.
Moon Surgical
Debt Financing in 2020
Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.
ABC Transfer
Series A in 2020
ABC Transfer is a biopharmaceutical company specializing in the development of Rapid Transfer Systems (RTS) solutions. It manufactures secure transfer systems specifically designed for sterile drug manufacturing and bioprocessing. The company's innovative systems utilize patented components such as alpha doors, beta containers, and single-use bags. These systems enhance sterility assurance, promote operator safety, and improve overall efficiency in pharmaceutical manufacturing processes.
Quantum Surgical
Grant in 2020
Quantum Surgical develops surgical robotics and intelligent tools to democratize minimally invasive liver cancer treatment. The company's robotics support percutaneous ablation therapies and related minimally invasive procedures, aiming to improve patient outcomes and safety in interventional oncology. By enabling precise robotic assistance, Quantum Surgical seeks to help healthcare providers perform safer, more effective liver cancer interventions, with potential for higher cure rates and shorter recovery times.
UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.
UroMems
Debt Financing in 2020
UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.
Dianosic
Seed Round in 2020
Founded in 2017, Dianosic specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. The company's flagship product is the Active Resorbable Intranasal Scaffold (ARIS), a long-acting, patient-friendly device designed to treat chronic rhinitis and sinusitis, offering an alternative to daily medication.
Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.
Multiwave Technologies
Grant in 2020
Multiwave Technologies develops breakthrough magnetic resonance imaging and positron emission tomography devices, including metamaterial MRI antennas designed by its French unit. The company aims to improve MRI image quality and support clinical decision making, including portable MRI capabilities and sensor-based performance analysis. Founded in 2015 in Switzerland, it is headquartered in Geneva and conducts research and development in France, reflecting an international footprint. The business is recognized for its metamaterial MRI antenna design and positions itself as a deep science imaging innovator in neurology and other medical imaging applications.
Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.
Laclarée
Seed Round in 2019
Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.
TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.
TreeFrog Therapeutics
Grant in 2019
TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.
BioSerenity
Series B in 2019
BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.
Volta Medical
Debt Financing in 2019
Founded in 2016 and based in Marseille, France, Volta Medical develops artificial intelligence software for interventional cardiology. Its flagship product, AIFib, assists cardiologists in treating atrial fibrillation by analyzing electrograms and guiding cardiac ablation procedures.
Neurallys
Seed Round in 2019
Neurallys is a Paris-based company that specializes in developing and producing medical devices focused on neurology and neurosurgery. The company has created an intelligent sensor that communicates with a smartphone to monitor intracranial pressure in patients suffering from hydrocephalus. This innovative device aims to enhance patient comfort and provides neurosurgeons with an effective tool for monitoring and managing the condition. By facilitating better follow-up care, Neurallys' technology seeks to improve the overall quality of treatment for individuals affected by this pathology.
Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.
Founded in 2017, Igyxos specializes in developing innovative pharmaceuticals and medical technologies focused on human fertility. The company supports the transfer of potential drug candidates to pre-clinical and clinical phases of development.
TreeFrog Therapeutics
Grant in 2019
TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.
SuperSonic Imagine
Post in 2018
SuperSonic Imagine SA is a medical technology company based in Aix-en-Provence, France, specializing in the development and manufacture of ultrasound imaging systems. Founded in 2005, the company is recognized for its Aixplorer system, which delivers high-definition, high-contrast imaging crucial for diagnosing and monitoring various conditions, including breast, prostate, and thyroid cancers, as well as liver diseases. SuperSonic Imagine also offers the ShearWave technology platform, which focuses on quantitative elastography for assessing tissue elasticity. The company operates primarily in France, the United States, and China, and distributes its products through a network of offices and partners across various countries, including Belgium, Germany, and the United Kingdom. As a subsidiary of Hologic Hub Ltd, SuperSonic Imagine continues to innovate in the field of medical imaging technology, enhancing the capabilities of healthcare practitioners.
Lattice Medical
Seed Round in 2018
Lattice Medical is a French medical device company focused on breast reconstruction after cancer. It designs and manufactures implantable devices that promote regeneration of autologous adipose tissue to enable natural breast reconstruction following mastectomy. The flagship implant, MATTISSE, uses 3D printing and fully biodegradable materials to provide personalized reconstruction in a single surgery, reducing operative time and invasiveness. The company aims to offer an alternative to silicone-based implants by supporting tissue regeneration rather than replacement. Founded in 2017 and based in Loos, France, Lattice Medical develops solutions to address clinical and societal needs by restoring form and function for women recovering from breast cancer.
C4Diagnostics
Seed Round in 2018
C4Diagnostics is a developer of in vitro diagnostic (IVD) kits that leverages proprietary technology to enhance the speed and sensitivity of diagnostic testing. The company focuses on creating medical devices and equipment that streamline the screening process for urinary tract infections, allowing for the reliable detection, counting, and concentration of relevant microorganisms in clinical microbiology. By enabling hospitals and laboratories to conduct culture-based IVD tests and specific fluorescence assessments, C4Diagnostics contributes to more efficient and effective diagnostic practices in healthcare settings.
Isorg SA, founded in 2010 and based in Grenoble, France, specializes in the development and manufacturing of organic and printed electronic devices, particularly in the fields of photonics and image sensors. The company is noted for its innovative high-performance opto-electronic sensors, which can be integrated into various products, transforming surfaces made of plastic or glass into smart interfaces. Isorg offers a comprehensive range of services, from proof-of-concept to mass production, catering to diverse applications across consumer electronics, home appliances, smart buildings, industrial sectors, healthcare, and safety. Additionally, the company provides support for product development and integration. Its technology includes large-area image sensors and photodetectors, contributing to sectors such as medical imaging, non-destructive testing, and data security.
Therachon
Series B in 2018
Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.
LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.
eCential Robotics
Series B in 2018
eCential Robotics specializes in minimally invasive surgical solutions aimed at enhancing routine clinical practices. The company develops advanced imaging technology that integrates fluoroscopy, surgical navigation, and robotics, specifically tailored for orthopedic and trauma surgeries. Its innovative system offers high-definition imaging and real-time navigation, allowing surgeons to conduct various procedures with increased safety and precision. By facilitating day surgery, eCential Robotics provides significant benefits to patients, hospitals, clinics, and overall healthcare systems, while also minimizing radiation exposure during complex interventions.
Fizimed
Seed Round in 2018
Fizimed SAS is a French company based in Strasbourg that specializes in developing medical devices aimed at addressing urinary incontinence in women. The company's flagship product, EMY, is a perineal probe designed to facilitate pelvic floor muscle reeducation. EMY connects to a mobile application, allowing users to engage in customized, interactive exercises that strengthen their pelvic floor while tracking their progress in real time. The device incorporates gamified elements to motivate users, offering various activities that turn exercises into enjoyable challenges. Founded in 2017, Fizimed is committed to balancing the safety and quality of medical devices with user-friendly technology, while actively working to destigmatize urinary incontinence—a common issue affecting one in ten women. Through social media initiatives, Fizimed fosters a community that encourages open discussions around this topic, aiming to empower women to take control of their health and well-being.
Belovia
Private Equity Round in 2017
Belovia is a company that focuses on designing, manufacturing, and marketing medical devices and equipment aimed at enhancing patient care and mobility in post-surgical hospital settings. Its product line includes electronic stocking donners, which assist both the general public and medical professionals in helping patients with mobility challenges. Additionally, the company offers light solutions designed for physical mobilization, catering particularly to the elderly. Belovia's devices are engineered to support caregivers in their efforts to maintain patient dignity and facilitate pride in their caregiving roles. Through its innovative solutions, Belovia aims to improve the overall experience for patients and healthcare providers alike.
Wandercraft
Series B in 2017
Wandercraft is a robotics company that develops self-balancing robotic exoskeletons to enable paralyzed users to stand and walk hands-free, without crutches. Its flagship exoskeleton, Atalante, is a commercial device designed for daily life and rehabilitation, CE-marked in 2019 and marketed to European rehab hospitals to support gait re-learning. The company combines algorithmics, AI, robotics, production, clinical, marketing and sales to deliver a full-stack solution and aims to bring a realistic, autonomous walking device beyond lab prototypes. The exoskeleton uses motors at each joint controlled by a computing unit running software that computes robotic algorithms every millisecond to replicate a human gait, enabling paraplegic individuals to regain autonomy during daily activities.
BioSerenity
Series A in 2017
BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.
Nomadeec
Venture Round in 2017
Nomadeec is a French mobile telemedicine platform specializing in remote medical decision-making for emergency and scheduled care. It caters to various healthcare professionals such as emergency doctors, sports doctors, paramedics, and others who require urgent intervention or teleconsultations.
Therachon
Series A in 2017
Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.
UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.
CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.